Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immune globulin - Takeda

Next Previous
Drug Profile

Immune globulin - Takeda

Alternative Names: 10% HyQ; 20% Solution with Recombinant Human Hyaluronidase (rHuPH20); 20% SubQ; CUVITRU; Cuvitru; DEQSIGA; Gammagard Liquid; GAMMAGARD LIQUID ERC; Gammagard S/D; Human Immune Globulin for Subcutaneous Administration; HyQ; HYQVIA; HyQvia; Ig20Gly; IGI 10% with rHuPH20; IGIV - Baxalta; IGSC - Baxalta; immune globulin intravenous; IVIG 10%; Kiovig; SCIG 20%; SHP-671; TAK 771; TAK-339; TAK-664; TAK-880; TAK-881

Latest Information Update: 03 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Baxter International
  • Developer Baxter International; Halozyme Therapeutics; Shire; Takeda
  • Class Anti-infectives; Anti-inflammatories; Antibacterials; Antidementias; Antifibrotics; Antivirals; Eye disorder therapies; Immunoglobulins; Immunoproteins; Polyethylene glycols; Serum globulins; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Immunoglobulin replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic inflammatory demyelinating polyradiculoneuropathy; Peripheral nervous system diseases
  • New Molecular Entity No

Highest Development Phases

  • Marketed Allotransplant rejection; Chronic lymphocytic leukaemia; Guillain-Barre syndrome; HIV infections; Idiopathic thrombocytopenic purpura; Immunodeficiency disorders; Multifocal motor neuropathy
  • Registered Agammaglobulinaemia; Chronic inflammatory demyelinating polyradiculoneuropathy
  • Phase II Ataxia
  • Discontinued Alzheimer's disease

Most Recent Events

  • 30 Jul 2025 Registered for Chronic inflammatory demyelinating polyradiculoneuropathy in Japan (IV) (Takeda pipeline, July 2025)
  • 30 Jul 2025 Registered for Multifocal motor neuropathy in Japan (SC) (Takeda pipeline, July 2025)
  • 30 Jun 2025 Takeda anticipates commercialization of GAMMAGARD LIQUID ERC to begin in the EU in 2027

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top